Ascendis Pharma A/S (NASDAQ:ASND) Rating Lowered to “Sell” at StockNews.com

Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday.

A number of other brokerages have also issued reports on ASND. Oppenheimer restated an “outperform” rating and set a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. Bank of America upped their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Jefferies Financial Group lifted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Wedbush raised Ascendis Pharma A/S to a “strong-buy” rating in a report on Monday, November 4th. Finally, TD Cowen lifted their target price on Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $195.92.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $126.03 on Tuesday. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The business has a fifty day moving average price of $132.04 and a 200-day moving average price of $132.86. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of -13.54 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, equities research analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP boosted its stake in shares of Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after acquiring an additional 170,942 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares during the period. Capital International Investors increased its position in shares of Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after buying an additional 10,044 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after buying an additional 155,971 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.